3 May 2022
SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022
Paris, May 3, 2022 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases, a genomic medicine company developing vision saving treatments for ocular diseases, announces today that it has been selected for an oral presentation at the ASGCT 25th Annual Meeting, taking place May 16-19, 2022 in Washington D.C.
Dr. Florence Lorget, Chief Development Sciences Officer at SparingVision, will present pharmacology and safety data on its lead product SPVN06, a gene and mutation-independent gene therapy developed in Retinitis Pigmentosa.
More information below:
Oral Presentation: SPVN06, a Novel Mutation-Independent AAV-Based Gene Therapy, Dramatically Reduces Vision Loss in the rd10 Mouse Model of Rod-Cone Dystrophy and is Well Tolerated in a 1-Month Pilot Safety Monkey Study
Date and Time: 19 May, 10:45AM- 11:AM EDT, Salon G
Presenter: Dr. Florence Lorget
Session Title: Ophthalmic and Auditory Diseases
NOTES TO EDITORS:
SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments. Leveraging its unparalleled understanding of retinal diseases, SparingVision has built the world’s most compelling portfolio of synergistic cutting-edge gene therapy and genome editing treatments for inherited retinal diseases (IRDs). Both of its most advanced products, SPVN06 and SPVN20 look to go beyond single gene correction therapies to deliver new mutation agnostic treatments for Retinitis Pigmentosa (RP), a group of IRDs which are the leading cause of blindness globally. The Company also has a strategic collaboration with Intellia Therapeutics (NASDAQ:NTLA) to develop novel genome editing-based treatments for ocular diseases utilizing CRISPR-Cas9 technology.
SparingVision is backed by high-quality international investors including 4BIO Capital, AdBio Partners, Bpifrance, Foundation Fighting Blindness (US), Fondation Voir & Entendre, Intellia Therapeutics, UPMC Enterprises, Jeito Capital, Ysios Capital.
Visit www.sparingvision.com for more and follow us on LinkedIn and Twitter @SparingVision.
SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress which, acting synergistically, aim at slowing or stopping the degeneration of cone photoreceptors, which inevitably leads to blindness in patients with rod-cone dystrophies (RCD). SparingVision’s primary disease target is Retinitis Pigmentosa (RP), one of the most common inherited retinal diseases that affects two million patients worldwide. There is currently no treatment approved to treat RP patients independently of their genetic background. This approach is potentially applicable to many more diseases where the loss of rods is known to be an early signal of the disease. First-in-man trials, with SPVN06 in patients with RP, will be commencing in H2 2021.
Stéphane Boissel, President and CEO
Nathalie Trepo, Investor Relations
Consilium Strategic Communications
Amber Fennell, Genevieve Wilson, Davide Salvi
+44 (0)20 3709 5700